A randomized comparison of etoposide and cyclophosphamide for stem cell mobilization in newly diagnosed multiple myeloma
) for stem cell mobilization in NDMM patients. Based on these findings, etoposide may be considered a more effective and safer option for stem cell mobilization in clinical practice.The clinical trial was registered on 24/08/2022 (clinical trial identifier NCT05517213).
Authors
- Shunzong Yuan (ORCID: https://orcid.org/0000-0002-8981-0397)
- Jieping Li (ORCID: https://orcid.org/0000-0002-3514-5467)
- M. Li
- Jie Chen (ORCID: https://orcid.org/0000-0003-3435-0351)
- Wenrong Huang (ORCID: https://orcid.org/0000-0002-9853-5446)
- XiuBin Xiao
- Yao Sun
- Yun Lu
- Xilin Chen
- Yi Ma
- Yao Liu
- Wen Gao
- Yujun Dong
Institutions
- Peking University (CN)
- People's Liberation Army No. 150 Hospital (CN)
- Beijing Anding Hospital (CN)
- Peking University First Hospital (CN)
- Chongqing Cancer Hospital (CN)
- Beijing Fengtai Hospital (CN)
- Chinese People’s Liberation Army 263 hospital (CN)
- Beijing Chaoyang Emergency Medical Center (CN)
- University of South China (CN)
Publication Details
- Journal
- Scientific Reports
- Published
- 2026-04-02
- DOI
- https://doi.org/10.1038/s41598-026-46787-1
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- General Hospital of People’s Liberation Army